💬In plain words
What the trial is, and whether it could suit you
This clinical study is designed to evaluate the efficacy and safety of a dietary supplement CL-P24113a for the management of androgenetic alopecia (AGA) in male subjects aged 18 to 45 years who suffer from alopecia with low hair density, classified as mild to moderate (Hamilton-Norwood stages II, III, and IV). The product is a formulation based on a blend of botanical ingredients and other well-established compounds, including Pumpkin Seed Oil (Curcubita pepo), Saw Palmetto Oil (Serenoa repens), L-Cystine, Prunus africana Bark Extract (Pygeum africanum), Horsetail Extract (Equisetum arvense), Olive Leaf Extract, among other excipients. These components have a well-documented history of safe use in both topical and oral applications with supporting safety information from international bodies such as EFSA. In this instrumental, single-blind, placebo-controlled study, 45 volunteers will be
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Written consent for LOPD compliance.
* Written informed consent for study DC.506.36.117.
* Gender: Male.
* Age: Between 18 and 45 years.
* Diagnosis of alopecia with low hair density, classified as mild to moderate (stages II, III, and IV on the Hamilton-Norwood scale).
Willingness to have a 1-2 cm² area shaved throughout the study period.
* Last participation in a clinical study on hair health must have ended at least six months before the start of this study.
* 30-day washout period without specific hair treatments (using a neutral shampoo).
* No use of any other topical or oral hair treatments in the target area during the study period; if necessary, consultation with the principal investigator is required to evaluate continued study participation.
Exclusion Criteria:
* Individuals with gastrointestinal diseases (e.g., diabetes, gastritis, Crohn's disease, celiac disease, ulcers, intolerances, etc.).
* Individuals with other physiological disorders (e.g., diabetes, hypertension, dyslipidemia) and/or gallstones.
* Individuals undergoing medical treatment in the weeks prior to the study that may interfere with study assessments (as determined by the investigator), particularly those who are currently taking or have taken 5α-reductase inhibitors (Finasteride, Dutasteride, Minoxidil, etc.) within the last three months.
Individuals who have undergone hair restoration treatments at any point in their lives, including hair transplants, mesotherapy, or platelet-rich plasma (PRP) therapy.
* Individuals following an atypical diet or planning to change their dietary routine during the study period.
* Individuals enrolled in another clinical study with similar characteristics (as determined by the investigator) during the study period.
* Individuals who are unable to fully understand the informed consent document or adhere to the study protocol.
DermaClaim
Valencia, Spain
DermaClaim
Valencia, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky